Drugs in Development
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IkT-148x
Therapeutic Area: Neurology Product Name: IkT-148x
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Details:
IkT-148x is c-Abl kinase inhibitor for treatment of Parkinson's disease and multiple system atrophy. A study revealed that c-Abl activates and regulates alpha-synuclein aggregation in the brains of MSA patients and in the brains of animal models of the disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): THX-160
Therapeutic Area: Neurology Product Name: THX-160
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Therapix Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 02, 2020
Details:
This collaboration is expected to facilitate the further development of THX-160 for the treatment of pain, following efficacy pre-clinical studies that demonstrated the analgesic advantages of THX-160 over control.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): QRA-244
Therapeutic Area: Neurology Product Name: QRA-244
Highest Development Status: Preclinical Product Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2020
Details:
Poster titled "QRA-244 a Potent, Selective KCNQ2/3 Opener and a Potential Therapy for Motor System Hyperexcitability induced Disease Progression in ALS patients " wail be presented MNDA 31st International Symposium on ALS/MND.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): HTL0022562
Therapeutic Area: Neurology Product Name: HTL0022562
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Biohaven Pharmaceuticals
Deal Size: $10.0 million Upfront Cash: $380.0 million
Deal Type: Collaboration December 01, 2020
Details:
Biohaven will get exclusive global rights to develop, manufacture and commercialize a portfolio of novel, small-molecule CGRP receptor antagonists discovered by Sosei Heptares for the treatment of CGRP-mediated disorders. The portfolio includes the lead candidate HTL0022562.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Bryostatin 1,Tretinoin
Therapeutic Area: Neurology Product Name: APH-1104
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
Details:
The combination therapeutic consists of biodegradable polymer nanospheres co-encapsulating a Bryoid and a Retinoid to improve synergistically alpha-secretase (α-secretase) production and reduce -amyloid plaque generation.
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
